Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858645 · ClinicalTrials.gov registry record · Phase 4
Correction of Psoriatic T Cell Signatures by Deucravacitinib
A Phase 4 study of Psoriasis Vulgaris, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05858645: Recruiting Phase 4 study of Psoriasis Vulgaris, sponsored by University of California, San Francisco.
NCT05858645 is a Phase 4 study of Psoriasis Vulgaris that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 25 participants, below the 88-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05858645, a Phase 4 study of Psoriasis Vulgaris, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Primary Outcome
Change in severity and extent of psoriasis (calculated by Psoriasis Area and Severity Index (PASI) score); scale range of 0 to 72, 72 being maximal disease
Conditions Studied
Interventions
- DRUG deucravacitinib
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
What NCT05858645 shows while recruiting
NCT05858645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 88-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Psoriasis Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which deucravacitinib is the first listed.
NCT05858645 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05858645 about?
NCT05858645 is a clinical study titled "Correction of Psoriatic T Cell Signatures by Deucravacitinib". This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
What is the current status of trial NCT05858645?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2023-10-01. Estimated completion is 2026-06.
What conditions does trial NCT05858645 study?
This clinical trial studies the following conditions: Psoriasis Vulgaris.
What interventions are being tested in trial NCT05858645?
The interventions under investigation include: deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT05858645?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05858645 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
RECRUITING · Phase 3
-
Use of Botulinum Toxin to Treat Psoriasis
COMPLETED · Phase 1
-
Blue Light Phototherapy
COMPLETED · NA
-
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
COMPLETED · Phase 2
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
COMPLETED · Phase 1
-
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI